DEPARTMENT OF LATENT INFECTION

The Department of Latent Infection (DLI) has been established in 2025 as a responding measure against contemporary challenges of microbial pathogenesis. Mainly aiming chronic and persistent infections, DLI addresses mucosal viral infections (Division I) and urogenital bacterial infections (Division II) via an ensemble of epidemiological, basic, and modality R&D research.

DIVISION I (LABORATORY OF MUCOSAL VIRAL INFECTION)

This laboratory mainly focuses on characterization and eff icient modality-based induction of mucosal viral infection-related antiviral innate and adaptive immunity. Based on development of various animal models during previous conjunction with AIDS Research Center (ARC), this division lays emphasis on development of both specif ic and pan-tropic antiviral modalities.

DIVISION II (LABORATORY OF UROGENITAL INFECTION)

The research activities in this division are as follows; classif ication, identif ication, serotyping and molecular typing of pathogenic bacteria described below for the diagnosis and investigation of community- and hospital- acquired bacterial infections. Molecular analysis of virulence of such bacteria has been intensively made, which outcomes are applied to the development of new methods for early diagnosis, and effective treatment and prevention. Based on conjunction with Department of Bacteriology I, this laboratory focuses mainly on the following three: Molecular analysis of virulence, and development and evaluation of diagnostic assays for syphilis. Molecular analysis of virulence and diagnosis of drug resistance in urogenital infectious bacteria. Molecular analysis and surveillance of Neisseria meningitidis

DEPARTMENT OF LATENT INFECTION Contents (Coming Soon)